Ionizing radiation in glioblastoma initiating cells

Frontiers in Oncology

Volumn 3 APR, Issue , 2013, Pages

  Rivera, Maricruz ^a,b   Sukhdeo, Kumar ^a,b   Yu, Jennifer ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C MET; DNA damage response; Glioma initiating cells; NOTCH; Radiation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; CABOZANTINIB; CEDIRANIB; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DOVITINIB; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

DNA DAMAGE; DOUBLE STRANDED DNA BREAK; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 84885436150     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00074     Document Type: Short Survey

References (70)

1. Abounader, R., Ranganathan, S., Lal, B., Fielding, K., Book, A., Dietz, H., et al. (1999). Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. 91, 1548-1556.
2. Amgen. (2012). Analysis of Rilotumumab (AMG 102) Data Identifies a Potential Predictive Biomarker for Patients with Gastric or Gastroesophageal Cancer [Press Release]. Available at: http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1696824
3. Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M. A., et al. (2010). TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18, 655-668.
4. Bao, S., Wu, Q., Li, Z., Sathornsumetee, S., Wang, H., McLendon, R. E., et al. (2008). Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68, 6043-6048.
5. Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
6. Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., et al. (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752. doi:10.1371/journal.pone.0007752
7. Calabrese, C., Poppleton, H., Kocak, M., Hogg, T. L., Fuller, C., Hamner, B., et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
8. Cancer Genome Atlas Research, N. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068.
9. Cao, B., Su, Y., Oskarsson, M., Zhao, P., Kort, E. J., Fisher, R. J., et al. (2001). Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U.S.A. 98, 7443-7448.
10. Chan, J. L., Lee, S. W., Fraass, B. A., Normolle, D. P., Greenberg, H. S., Junck, L. R., et al. (2002). Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin. Oncol. 20, 1635-1642.
11. Charles, N., and Holland, E. C. (2010). The perivascular niche microenvironment in brain tumor progression. Cell Cycle 9, 3012-3021.
12. Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
13. De Bacco, F., Casanova, E., Medico, E., Pellegatta, S., Orzan, F., Albano, R., et al. (2012). The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res. 72, 4537-4550.
14. De Bacco, F., Luraghi, P., Medico, E., Reato, G., Girolami, F., Perera, T., et al. (2011). Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst. 103, 645-661.
15. Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., et al. (2012). Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756-784.
16. Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., et al. (2010). NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28, 5-16.
17. Firat, E., Gaedicke, S., Tsurumi, C., Esser, N., Weyerbrock, A., and Niedermann, G. (2011). Delayed cell death associated with mitotic catastrophe in gamma-irradiated stem-like glioma cells. Radiat. Oncol. 6, 71.
18. Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., et al. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021.
19. Gatenby, R. A., and Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899.
20. Guo, Z., Kumagai, A., Wang, S. X., and Dunphy, W. G. (2000). Requirement for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA replication blocks and UV-damaged DNA in Xenopus egg extracts. Genes Dev. 14, 2745-2756.
21. Guruharsha, K. G., Kankel, M. W., and Artavanis-Tsakonas, S. (2012). The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat. Rev. Genet. 13, 654-666.
22. Hardee, M. E., Marciscano, A. E., Medina-Ramirez, C. M., Zagzag, D., Narayana, A., Lonning, S. M., et al. (2012). Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res. 72, 4119-4129.
23. Heddleston, J. M., Li, Z., McLendon, R. E., Hjelmeland, A. B., and Rich, J. N. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8, 3274-3284.
24. Hitoshi, S., Alexson, T., Tropepe, V., Donoviel, D., Elia, A. J., Nye, J. S., et al. (2002). Notch pathway molecules are essential for the maintenance, but not the generation, of mammalian neural stem cells. Genes Dev. 16, 846-858.
25. Hjelmeland, A. B., Wu, Q., Heddleston, J. M., Choudhary, G. S., MacSwords, J., Lathia, J. D., et al. (2011). Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ. 18, 829-840.
26. Hochberg, F. H., and Pruitt, A. (1980). Assumptions in the radiotherapy of glioblastoma. Neurology 30, 907-911.
27. Hovinga, K. E., Shimizu, F., Wang, R., Panagiotakos, G., Van Der Heijden, M., Moayedpardazi, H., et al. (2010). Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28, 1019-1029.
28. Ignatova, T. N., Kukekov, V. G., Laywell, E. D., Suslov, O. N., Vrionis, F. D., and Steindler, D. A. (2002). Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39, 193-206.
29. Jeon, H. M., Jin, X., Lee, J. S., Oh, S. Y., Sohn, Y. W., Park, H. J., et al. (2008). Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev. 22, 2028-2033.
30. Jin, J., Bae, K. H., Yang, H., Lee, S. J., Kim, H., Kim, Y., et al. (2011). In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug. Chem. 22, 2568-2572.
31. Joo, K. M., Jin, J., Kim, E., Ho Kim, K., Kim, Y., Gu Kang, B., et al. (2012). MET signaling regulates glioblastoma stem cells. Cancer Res. 72, 3828-3838.
32. Kim, K. H., Seol, H. J., Kim, E. H., Rheey, J., Jin, H. J., Lee, Y., et al. (2013). Wnt/beta-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro-oncology 15, 161-171.
33. Kong, D. S., Song, S. Y., Kim, D. H., Joo, K. M., Yoo, J. S., Koh, J. S., et al. (2009). Prognostic significance of c-Met expression in glioblastomas. Cancer 115, 140-148.
34. Lal, B., Xia, S., Abounader, R., and Laterra, J. (2005). Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res. 11, 4479-4486.
35. Laperriere, N. J., Leung, P. M., McKenzie, S., Milosevic, M., Wong, S., Glen, J., et al. (1998). Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 41, 1005-1011.
36. Lee, S. W., Fraass, B. A., Marsh, L. H., Herbort, K., Gebarski, S. S., Martel, M. K., et al. (1999). Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. 43, 79-88.
37. Li, Y., Guessous, F., Zhang, Y., Dipierro, C., Kefas, B., Johnson, E., et al. (2009). MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69, 7569-7576.
38. Li, Y., Li, A., Glas, M., Lal, B., Ying, M., Sang, Y., et al. (2011). c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc. Natl. Acad. Sci. U.S.A. 108, 9951-9956.
39. Lin, J., Zhang, X. M., Yang, J. C., Ye, Y. B., and Luo, S. Q. (2010). gamma-secretase inhibitor-I enhances radiosensitivity of glioblastoma cell lines by depleting CD133+ tumor cells. Arch. Med. Res. 41, 519-529.
40. Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I. R., et al. (2006). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67.
41. Liu, X., Newton, R. C., and Scherle, P. A. (2010). Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol. Med. 16, 37-45.
42. Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., et al. (2012). VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35.
43. Maher, E. A., Brennan, C., Wen, P. Y., Durso, L., Ligon, K. L., Richardson, A., et al. (2006). Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 66, 11502-11513.
44. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R. III, Hurov, K. E., Luo, J., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166.
45. Matsuoka, S., Huang, M., and Elledge, S. J. (1998). Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893-1897.
46. National Cancer Institute (NCI). (2000). "RO4929097 and bevacizumab in treating patients with progressive or recurrent malignant glioma," in ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT01189240 [cited Dec 12, 2012].
47. Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173.
48. Princess Margaret Hospital, National Cancer Institute (NCI). (2000a). "Gamma-secretase inhibitor RO4929097 and cediranib maleate in treating patients with advanced solid tumors," in ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT01131234 [cited Dec 12, 2012].
49. Princess Margaret Hospital, National Cancer Institute (NCI). (2000b). "RO4929097 in treating patients with recurrent invasive gliomas," in ClinicalTrials.gov[Internet]. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT01269411 [cited Dec 12, 2012].
50. Rizzo, P., Osipo, C., Foreman, K., Golde, T., Osborne, B., and Miele, L. (2008). Rational targeting of Notch signaling in cancer. Oncogene 27, 5124-5131.
51. Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., and Wrensch, M. (2006). Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2, 494-503. [quiz 491 p. following 516].
52. Seidel, S., Garvalov, B. K., Wirta, V., Von Stechow, L., Schanzer, A., Meletis, K., et al. (2010). A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133, 983-995.
53. Selker, R. G., Shapiro, W. R., Burger, P., Blackwood, M. S., Arena, V. C., Gilder, J. C., et al. (2002). The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51, 343-355; discussion 355-347.
54. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
55. Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., et al. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
56. Snuderl, M., Fazlollahi, L., Le, L. P., Nitta, M., Zhelyazkova, B. H., Davidson, C. J., et al. (2011). Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20, 810-817.
57. Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28, 3949-3959.
58. Son, M. J., Woolard, K., Nam, D. H., Lee, J., and Fine, H. A. (2009). SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440-452.
59. Souhami, L., Seiferheld, W., Brachman, D., Podgorsak, E. B., Werner-Wasik, M., Lustig, R., et al. (2004). Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60, 853-860.
60. Stockhausen, M. T., Kristoffersen, K., and Poulsen, H. S. (2010). The functional role of Notch signaling in human gliomas. Neuro-oncology 12, 199-211.
61. Stupp, R., Hegi, M. E., Mason, W. P., Van Den Bent, M. J., Taphoorn, M. J., Janzer, R. C., et al. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.
62. Sydney Kimmel Comprehensive Cancer Center, National Cancer Institute (NCI). (2000). "RO4929097 in treating patients with recurrent or progressive glioblastoma," in ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/ct2/show/NCT01122901 [cited Dec 12, 2012].
63. Tamura, K., Aoyagi, M., Wakimoto, H., Ando, N., Nariai, T., Yamamoto, M., et al. (2010). Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J. Neurosurg. 113, 310-318.
64. Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110.
65. Wang, J., Sullenger, B. A., and Rich, J. N. (2012). Notch signaling in cancer stem cells. Adv. Exp. Med. Biol. 727, 174-185.
66. Wang, J., Wakeman, T. P., Lathia, J. D., Hjelmeland, A. B., Wang, X. F., White, R. R., et al. (2010). Notch promotes radioresistance of glioma stem cells. Stem Cells 28, 17-28.
67. Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773.
68. Zhang, Y., Guessous, F., Kofman, A., Schiff, D., and Abounader, R. (2010). XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 13, 112-121.
69. Zhou, B. B., and Elledge, S. J. (2000). The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439.
70. Zhu, T. S., Costello, M. A., Talsma, C. E., Flack, C. G., Crowley, J. G., Hamm, L. L., et al. (2011). Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 71, 6061-6072.